Raising awareness and funds for DIPG brain tumour research.
Raising awareness and pursuing equitable funding for paediatric palliative care in NZ.
Welcome to Jemima’s Wish
NEWS FLASH
“A robot, bought with the money Jemima crowdfunded in the weeks before succumbing to brain cancer, is doing the job she assigned – finding a way to save other children from the “monster” that claimed her young life.…”
Our mission
Jemima’s Wish is a registered charitable trust that exists to do 2 things.
Firstly, raising awareness of DIPG in medical and practical terms. Telling Jemima’s story and honouring her wish to defeat DIPG - so no other kid will be told they’ve got untreatable and incurable brain cancer. And to generate funding to help find the cure.
Secondly, the pursuit of equitable funding for specialist paediatric palliative care that seriously ill kids in NZ do not currently receive.
-
We knew nothing about DIPG and Paed Pall until we had to. This website exists to inform you about the disease, and the lack of funded paediatric compassionate care in NZ. And what that translated to in our experience.
-
Jemima’s Incredible Journey is a pretty amazing story of a regular teenage girl who walked through the fire, stared a terminal diagnosis in the eye, and evolved into a selfless heroine. Her story deserves to be shared.
-
Since Jemima’s Wish closed on the Give A Little platform, we’ve been asked numerous times how people can continue to support her work. We’ve created a Charitable Trust to do just that.
DIPG patients today face the same prognosis as a person diagnosed 50 years ago.
Brain tumours remain the most common cause of cancer-related death in children, and DIPG is the leading cause of death from paediatric brain tumours. There are no effective treatment options and no chance of survival. Only 10% of children with DIPG survive for 2 years following their diagnosis, and less than 1% survive for 5 years.
The median survival time is 9 months from diagnosis, after receiving palliative radiotherapy which is the only ‘standard of care’ treatment pathway.